Adocia Reacquires Exclusive Development Rights to Ultra-Fast Acting Insulin Analog

Adocia has announced that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone® technology for the formulation of fast acting insulin analog formulated with the BioChaperone® technology. Consequently, the two companies have terminated the collaboration.

“We intend to pursue more actively this project by ourselves as the phase I clinical trial met the predefined clinical endpoints, hence confirming the great potential of our BioChaperone® technology” said Gerard Soula, President and CEO, Adocia.

“Our plan is to test a BioChaperone® insulin analog formulation on type I diabetic patients. For this, we intend to conduct a clinical trial, before year end in Germany, on one or more formulations of insulin analog. This trial will be carried out in parallel to the one already scheduled with HinsBet®, our formulation of human insulin” said Olivier Soula, deputy general manager and director R&D, Adocia.

The company has a strong financial position enabling the development of this priority project at its own expense.

Next scheduled events
September 5, 2013: Publication of mid-year financial statements as of June 30, 2013.
September 6, 2013: Presentation meeting to investors (SFAF).